Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment

Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable disease

Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 months

Biomarker analysis confirms immune activation in the tumor microenvironment

Data Presented at Society for Immunotherapy of Cancer on November 8, 2024